TrueWealth LLC’s iShares US Pharmaceuticals ETF IHE Stock Holding History

TrueWealth LLC’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$29K	Buy	+570	New	+$28.7K	0.01%	340

Other funds holding IHE

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TrueWealth LLC's IHE Position: Q2 2020 in Review

TrueWealth LLC opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2020: 570 shares worth $29K. The stake represents 0.01% of the portfolio and ranks #340 among its holdings.

91 funds tracked by Wall St. Rank hold IHE as of Q2 2020.

TrueWealth LLC held 570 shares of iShares US Pharmaceuticals ETF worth $29K as of Q2 2020.
iShares US Pharmaceuticals ETF was a new TrueWealth LLC position in Q2 2020.
iShares US Pharmaceuticals ETF made up 0.01% of TrueWealth LLC's portfolio in Q2 2020, its #340 holding.
91 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2020.

Based on TrueWealth LLC's 13F filing for Q2 2020, filed 15 Jul 2020.